Quick answers
- What is Vimpat?
- Vimpat is a brand name of Lacosamide, a prescription medicine. The FDA NDC Directory lists 6 Vimpat products in 6 strengths and forms.
- Who makes Vimpat?
- Ucb Inc holds the FDA application for Vimpat (NDA022253, approved October 28, 2008).
- Is there a generic or store brand of Vimpat?
- Yes. The FDA NDC Directory lists 120 other products with the same active ingredients, strength and form as a Vimpat product, 120 of them generic. Ask your pharmacist whether one is right for you.
- What do pharmacies pay for Vimpat?
- CMS lists a National Average Drug Acquisition Cost (NADAC) for 5 Vimpat strengths and forms (see the table below). That is what pharmacies pay to buy it, not what you pay: your price depends on your insurance and your pharmacy.
- Has Vimpat been recalled?
- FDA enforcement reports list 1 recall of Vimpat products; the newest started March 15, 2021. A recall usually concerns specific lots, not every product.
What Vimpat is
Each Vimpat product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.
Lacosamide · prescription medicine
| Strength and form | Product names | Same medicine, other names | Label |
|---|---|---|---|
| lacosamide 10 mg/mL injection (intravenous) | Vimpat | 15 products, 14 companies | DailyMed |
| lacosamide 10 mg/mL solution (oral) | Vimpat | 18 products, 18 companies | DailyMed |
| lacosamide 100 mg tablet, film coated (oral) | Vimpat | 23 products, 21 companies | DailyMed |
| lacosamide 150 mg tablet, film coated (oral) | Vimpat | 19 products, 19 companies | DailyMed |
| lacosamide 200 mg tablet, film coated (oral) | Vimpat | 22 products, 22 companies | DailyMed |
| lacosamide 50 mg tablet, film coated (oral) | Vimpat | 23 products, 22 companies | DailyMed |
Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Lacosamide →
FDA approval
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| lacosamide 10 mg/mL solution | Brand: Vimpat | $2.30 per mL Generic of the same strength and form: $0.0831 per mL |
| lacosamide 100 mg tablet, film coated | Brand: Vimpat | $18.53 per tablet Generic of the same strength and form: $0.1887 per tablet |
| lacosamide 150 mg tablet, film coated | Brand: Vimpat | $19.65 per tablet Generic of the same strength and form: $0.2285 per tablet |
| lacosamide 200 mg tablet, film coated | Brand: Vimpat | $19.63 per tablet Generic of the same strength and form: $0.2518 per tablet |
| lacosamide 50 mg tablet, film coated | Brand: Vimpat | $11.83 per tablet Generic of the same strength and form: $0.1205 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list Vimpat
The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Vimpat products.
- UCB, Inc.6 products
Recalls
From FDA enforcement reports, matched by the product’s NDC code or label. A recall usually covers specific lots: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
March 15, 2021 · Class II · Terminated · D-0590-2021
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
VIMPAT (lacosamide) Tablets, 200mg, 60-count bottle, Rx Only, Manufactured for: UCB, Inc. Smyrna, GA 30080, NDC 0131-2480-35 — Cardinal Health Inc.
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026
Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.